The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Bimatoprost / Timolol preservative-free eye-drops (Ganfort® Unit Dose) have been accepted for restricted use in the treatment of open-angle glaucoma or ocular hypertension. The restriction limits use to patients who have proven sensitivity to preservatives.
Nalmefene (Selincro®) has been accepted for use in the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. It is recommended that this medication only be prescribed in conjunction with continuous psychosocial support and if the drinking risk level remains high two weeks after initial assessment.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Saxagliptin fails to reduce cardiovascular events||Drug Safety Update - October 2013 »|